R
Regulus Therapeutics
Regulus Therapeutics – A Leading microRNA Therapeutics Company | Regulus Therapeutics – a leading company developing microRNA therapeutics. Medicines that target the pathways of human disease.
About Regulus Therapeutics
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company that directs its efforts toward discovering and developing medicines that target microRNAs, which are small, non-coding RNA molecules involved in regulating gene expression. The company was established in September 2007 as a joint venture between two RNA-focused firms, Alnylam Pharmaceuticals and Isis Pharmaceuticals (now Ionis Pharmaceuticals). This formation combined the intellectual property and technological expertise of its parent companies, creating a significant force in the microRNA therapeutics space. Kleanthis G. Xanthopoulos was the founding President and CEO. Regulus went public in October 2012 with an IPO on the NASDAQ, raising approximately $80.9 million to advance its pipeline.
Read full description
The company's business model is centered on high-risk, high-reward research and development, which is typical for a clinical-stage entity. As such, revenue has been primarily generated through strategic collaborations and license agreements with larger pharmaceutical partners, including upfront payments, milestone payments, and potential future royalties. Significant alliances have been formed with companies like GlaxoSmithKline, Sanofi, and AstraZeneca for the development of microRNA therapeutics in areas such as inflammatory diseases and fibrosis. A substantial portion of the company's capital is reinvested into its R&D programs to advance its pipeline through preclinical and clinical trials.
Regulus focuses on developing treatments for genetically based orphan diseases with high unmet medical needs. Its core technology involves identifying microRNAs linked to specific diseases and then designing and synthesizing oligonucleotide therapeutics, or "anti-miRs," to modulate their activity. The company's lead product candidate is farabursen (also known as RGLS8429), a next-generation oligonucleotide designed to inhibit miR-17 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). ADPKD is a genetic disorder that causes cysts to grow in the kidneys, which can lead to kidney failure. Farabursen has shown in preclinical models and early clinical trials to improve kidney function and size. The drug has demonstrated a favorable safety and pharmacokinetic profile in Phase 1 clinical trials. In April 2025, Novartis announced an agreement to acquire Regulus, a deal centered on the potential of farabursen. As of June 2025, Regulus operates as a subsidiary of Novartis AG.
At a glance
- Status
- Listed
- Founded
- 2007
- Headquarters
- San Diego, United States
- Listing
- IPO 2012
- Employees
- 45
- Open positions
- None listed
- Dealroom signal
- 39.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Intellectual Property, Biotechnology, Oncology, Genetics and genomics, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Apr 2025 | $800M | — | Novartis | ↗ |
| PRIVATE PLACEMENT VCOther financing | Mar 2024 | $100M | — | NEA · Adage Capital · RA Capital Management · Deep Track Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$46M | — |
| 2025 | $0 | — | −$46M | — |
| 2024 | $0 | — | −$46M | — |
| 2023 | $0 | — | −$29M | — |
| 2022 | $0 | — | −$28M | — |
| 2021 | $0 | -100% | −$28M | — |
| 2020 | $10M | — | −$14M | -141.5% |
Growth signals
Latest recorded traffic for Regulus Therapeutics is 820 monthly website visits, down 78.4% over the last three months. Regulus Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 HistideBiotech intellectual property platform |
Feusisberg, Switzerland | Operational | 6 | $4.1M | — |
 Mediphage BioceuticalsCures for chronic diseases |
Toronto, Canada | Operational | |||
 AnchorDxAnchorDx is a precision medicine firm |
Guangzhou, China | Operational | |||
 GeneAdviserOur mission is to make genetic testing for rare diseases more accessible to clinicians around the world |
Cambridge, United Kingdom | Operational | |||
 GeneAssessNew jersey-based biotechnology company working to validate fry, a cancer molecular signature gene |
New Brunswick, United States | Operational | |||
 SequenomTechnologies and tools used in oncology, agricultural genomics, and in diagnosing prenatal and retinal disorders |
San Diego, United States | Acquired | |||
 AnnoroadA leading developer and marketer on genomic innovation technologies for research and clinical market |
Dongcheng District, China | Operational | |||
 Immunomic TherapeuticsImmunomic Therapeutics, Inc. |
Lancaster, United States | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Sanofi Aventis
Series B and later3 investors entered at this stage
Oxford Finance
Federated Hermes
NEA
Other known investors6 additional known investors
Adage Capital
Deep Track Capital
Novartis
Octagon Capital Advisors
RA Capital Management
Vivo Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Regulus Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Regulus Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.